Skip to main content

Ad19a/64 Adenoviral Vector

Ad19a/64 vector for vaccination

Our proprietary Ad19a/64 vector (Subtype D) can be used to overcome the low transduction efficiency of commonly used Ad serotypes and help overcome the challenge of pre-existing immunity. It is an attractive alternative for the most commonly used human adenovirus type 5 (Ad5) for specific types of applications.

Ad19a/64 is the first accessible subtype D adenovirus vector. This vector provides superior transduction of human cells (e.g., dendritic cells, cardiomyocytes, fibroblasts, PBMCs, myoblasts, and myotubes) when compared to Ad5. It also possesses CAR-independent binding properties, targeting sialic acid-dependent receptors. In preclinical vaccine studies, the vector induced superior levels of CD4 and CD8 immune responses in non-human primates.

Key benefits of our Ad19a/64 vector
  • Target new cell types/tissue due to its unique receptor affinities
  • Leverage its low seroprevalence within the human population
  • Superior vaccine vector platform compared to Ad5
  • Overcome limitations due to CAR-dependent transduction
Transduction experiments with human myoblasts and primary myotubes
Transduction of myoblasts with Ad5-EGFP (Ad5) and Ad19a/64-EGFP (Ad19a)

Primary myoblasts of human ape, pig, and mouse origin were transduced with 1250 VP/cell (green columns), 2500 VP/cell (black columns), and 12500 VP/cell (grey columns) respectively, and GFP expression was quantified after 48 hr. Each value represents the mean of transgene expression per well in relative light units (RLU) from five independent experiments +

MicrosoftTeams-image (16).png
Transduction of primary myotubes (MTs) with Ad5EGFP and Ad19a/64-EGFP

Ten-day-old human myotubes were transduced with 1250 VP/cell (green columns). 2500 VP/cell (black columns) and 12500 VP/cell (grey columns), respectively. GFP expression was quantified after 48 hrs. Each value represents the mean relative light units (RLU) of five independent transductions +/- SD

MicrosoftTeams-image (17).png
Ad19a/64 in mucosal boost immunization against SARS-CoV-2

In the course of the worldwide pandemic caused by SARS-CoV-2, German scientists tested Ad5 as well as Ad19a/64 to administer Spike S protein intranasally in mice. After plasmid DNA or mRNA priming before intranasal immunization, the group saw a strong systemic and mucosal immune reaction triggered by both vectors. The authors have shown the potential of using adenoviral vectors to boost mucosal immunity in mice. Additionally, the group described slight differences in the tropism of Ad5 and Ad19a/64 that require further investigation, especially when translating from animal studies to clinical testing.

Licensing information
Our Ad19a/64 vector is available for licensing.

If you are interested in this technology, please get in touch with our Business Development and Licensing team at Mun.Licensing@revvity.com

Questions?
We’re here to help.

Contact us

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.